People · Operator
Named in public records as an officer, director or promoter · active 2018–2026 · Biotechnology, Other
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Elcelyx Therapeutics, Inc. | — | Biotechnology | Series B | $73.4M | $18.9M | 2018 |
| Round 2 Holdings, LLC | — | Other | Series B | $35.5M | $137.4M | 2025 |
Richard Barry at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Richard Barry on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Bosun Hau | 1 | 6 |
| Ralph E. Christoffersen | 1 | 6 |
| Mark Morris | 1 | 3 |
| Jim Glasheen | 1 | 3 |
| RICHARD J. BARRY | 1 | 3 |
| Theodore A. Laufik | 1 | 2 |
| Brook J. Byers | 1 | 2 |
| Alain Baron | 1 | 2 |
| Brook R. Byers | 1 | 2 |
| Jason Drattell | 1 | 2 |
| Kevin Burke | 1 | 2 |
| Ginger E. Graham | 1 | 1 |
| Liang R. Tsui | 1 | 1 |
| Thomas Duffy | 1 | 1 |
| David Blatte | 1 | 1 |
| John Kobza | 1 | 1 |
| Ginger Graham | 1 | 1 |
| Mark Fineman | 1 | 1 |
| Christoffersen Ralph | 1 | 1 |
| Sandy Mahatme | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.